JP2004511773A - アフィニティ捕捉タンデム質量分析を用いた分子相互作用の特性を決定する方法 - Google Patents
アフィニティ捕捉タンデム質量分析を用いた分子相互作用の特性を決定する方法 Download PDFInfo
- Publication number
- JP2004511773A JP2004511773A JP2002534819A JP2002534819A JP2004511773A JP 2004511773 A JP2004511773 A JP 2004511773A JP 2002534819 A JP2002534819 A JP 2002534819A JP 2002534819 A JP2002534819 A JP 2002534819A JP 2004511773 A JP2004511773 A JP 2004511773A
- Authority
- JP
- Japan
- Prior art keywords
- binding partner
- probe
- protein
- binding
- affinity capture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 162
- 238000004885 tandem mass spectrometry Methods 0.000 title claims description 19
- 230000004001 molecular interaction Effects 0.000 title abstract description 4
- 239000000523 sample Substances 0.000 claims abstract description 259
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 159
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 157
- 238000001698 laser desorption ionisation Methods 0.000 claims abstract description 35
- 238000009739 binding Methods 0.000 claims description 203
- 230000027455 binding Effects 0.000 claims description 201
- 235000018102 proteins Nutrition 0.000 claims description 151
- 150000002500 ions Chemical class 0.000 claims description 116
- 239000012634 fragment Substances 0.000 claims description 66
- 238000004949 mass spectrometry Methods 0.000 claims description 57
- 238000004458 analytical method Methods 0.000 claims description 40
- 108020003175 receptors Proteins 0.000 claims description 38
- 102000005962 receptors Human genes 0.000 claims description 38
- 230000003993 interaction Effects 0.000 claims description 36
- 238000001179 sorption measurement Methods 0.000 claims description 26
- 239000012472 biological sample Substances 0.000 claims description 25
- 238000005259 measurement Methods 0.000 claims description 19
- 238000013467 fragmentation Methods 0.000 claims description 17
- 238000006062 fragmentation reaction Methods 0.000 claims description 17
- 238000001819 mass spectrum Methods 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 17
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 14
- 238000003776 cleavage reaction Methods 0.000 claims description 14
- 238000001360 collision-induced dissociation Methods 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 14
- 230000007017 scission Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 241000206602 Eukaryota Species 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 229910052751 metal Inorganic materials 0.000 claims description 10
- 239000002184 metal Substances 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 230000009149 molecular binding Effects 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 7
- 102000003886 Glycoproteins Human genes 0.000 claims description 7
- 108090000631 Trypsin Proteins 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 238000005349 anion exchange Methods 0.000 claims description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 238000001877 single-ion monitoring Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 108090001008 Avidin Proteins 0.000 claims description 5
- 108090001090 Lectins Proteins 0.000 claims description 5
- 102000004856 Lectins Human genes 0.000 claims description 5
- 101710118538 Protease Proteins 0.000 claims description 5
- 108010090804 Streptavidin Proteins 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 238000005341 cation exchange Methods 0.000 claims description 5
- 238000010494 dissociation reaction Methods 0.000 claims description 5
- 230000005593 dissociations Effects 0.000 claims description 5
- 239000002523 lectin Substances 0.000 claims description 5
- 239000007791 liquid phase Substances 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 108010059339 submandibular proteinase A Proteins 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 4
- 238000004891 communication Methods 0.000 claims description 4
- 230000006854 communication Effects 0.000 claims description 4
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 4
- 210000002751 lymph Anatomy 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 3
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims description 3
- 102000012479 Serine Proteases Human genes 0.000 claims description 3
- 108010022999 Serine Proteases Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000013060 biological fluid Substances 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 229910052697 platinum Inorganic materials 0.000 claims description 3
- 108010031896 Cell Cycle Proteins Proteins 0.000 claims description 2
- 102000005483 Cell Cycle Proteins Human genes 0.000 claims description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 2
- 102000002278 Ribosomal Proteins Human genes 0.000 claims description 2
- 108010000605 Ribosomal Proteins Proteins 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 210000001742 aqueous humor Anatomy 0.000 claims description 2
- 125000003700 epoxy group Chemical group 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 239000004031 partial agonist Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000004127 vitreous body Anatomy 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 3
- 241000283984 Rodentia Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 230000003100 immobilizing effect Effects 0.000 claims 2
- 241000251468 Actinopterygii Species 0.000 claims 1
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 102100021238 Dynamin-2 Human genes 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 claims 1
- 241000244206 Nematoda Species 0.000 claims 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 1
- 241000592342 Tracheophyta Species 0.000 claims 1
- GRSTVVGJSKHCCS-UHFFFAOYSA-N bis(1h-imidazol-2-yl)methanone Chemical group N=1C=CNC=1C(=O)C1=NC=CN1 GRSTVVGJSKHCCS-UHFFFAOYSA-N 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 102000027257 transmembrane receptors Human genes 0.000 claims 1
- 108091008578 transmembrane receptors Proteins 0.000 claims 1
- 239000007789 gas Substances 0.000 description 54
- 108090000765 processed proteins & peptides Proteins 0.000 description 49
- 238000003795 desorption Methods 0.000 description 48
- 238000013459 approach Methods 0.000 description 31
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 239000012491 analyte Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 23
- 239000003463 adsorbent Substances 0.000 description 21
- 230000003287 optical effect Effects 0.000 description 20
- 230000009870 specific binding Effects 0.000 description 20
- 230000008901 benefit Effects 0.000 description 19
- 239000013307 optical fiber Substances 0.000 description 18
- 239000000835 fiber Substances 0.000 description 17
- 239000003446 ligand Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 230000005284 excitation Effects 0.000 description 12
- 230000000717 retained effect Effects 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 102000007079 Peptide Fragments Human genes 0.000 description 11
- 108010033276 Peptide Fragments Proteins 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 239000003480 eluent Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000001444 catalytic combustion detection Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000007026 protein scission Effects 0.000 description 6
- 230000002797 proteolythic effect Effects 0.000 description 6
- 150000003384 small molecules Chemical class 0.000 description 6
- 238000000018 DNA microarray Methods 0.000 description 5
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 5
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 5
- 230000001133 acceleration Effects 0.000 description 5
- 238000011948 assay development Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005040 ion trap Methods 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 239000000091 biomarker candidate Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000009510 drug design Methods 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 230000009878 intermolecular interaction Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 201000001514 prostate carcinoma Diseases 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008241 heterogeneous mixture Substances 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910052756 noble gas Inorganic materials 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- -1 phosphorotriesters Chemical class 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002594 sorbent Substances 0.000 description 3
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000003766 bioinformatics method Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical group C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000004989 laser desorption mass spectroscopy Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000009120 phenotypic response Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- KEJYUAMBFQZVEH-UHFFFAOYSA-N 3-cyano-2-hydroxy-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(O)=C(C#N)C1=CC=CC=C1 KEJYUAMBFQZVEH-UHFFFAOYSA-N 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000582786 Monoplex Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000007813 chromatographic assay Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 238000001977 collision-induced dissociation tandem mass spectrometry Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000021040 cytoplasmic transport Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 230000035990 intercellular signaling Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 230000005596 ionic collisions Effects 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000005405 multipole Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000000955 peptide mass fingerprinting Methods 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/02—Details
- H01J49/10—Ion sources; Ion guns
- H01J49/16—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission
- H01J49/161—Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission using photoionisation, e.g. by laser
- H01J49/164—Laser desorption/ionisation, e.g. matrix-assisted laser desorption/ionisation [MALDI]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Plasma & Fusion (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/028261 WO2002031484A2 (en) | 2000-10-11 | 2000-10-11 | Methods for characterizing molecular interactions using affinity capture tandem mass spectrometry |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004511773A true JP2004511773A (ja) | 2004-04-15 |
| JP2004511773A5 JP2004511773A5 (enExample) | 2005-04-14 |
Family
ID=21741885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002534819A Pending JP2004511773A (ja) | 2000-10-11 | 2000-10-12 | アフィニティ捕捉タンデム質量分析を用いた分子相互作用の特性を決定する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20030219731A1 (enExample) |
| EP (1) | EP1327151A2 (enExample) |
| JP (1) | JP2004511773A (enExample) |
| CN (1) | CN1474944A (enExample) |
| AU (1) | AU1199501A (enExample) |
| CA (1) | CA2425434A1 (enExample) |
| WO (1) | WO2002031484A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106415260A (zh) * | 2014-06-13 | 2017-02-15 | Dh科技发展私人贸易有限公司 | 使用质谱分析法分析脂质的方法 |
| JP2017534052A (ja) * | 2014-10-30 | 2017-11-16 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | イオン断片化のためのイオンを選択するための方法およびシステム |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101555D0 (sv) * | 2001-05-04 | 2001-05-04 | Amersham Pharm Biotech Ab | Fast variable gain detector system and method of controlling the same |
| US6946653B2 (en) * | 2001-11-27 | 2005-09-20 | Ciphergen Biosystems, Inc. | Methods and apparatus for improved laser desorption ionization tandem mass spectrometry |
| US7846748B2 (en) * | 2002-12-02 | 2010-12-07 | The University Of North Carolina At Chapel Hill | Methods of quantitation and identification of peptides and proteins |
| CN1314968C (zh) * | 2004-03-11 | 2007-05-09 | 复旦大学 | 痕量多肽或蛋白质富集及其直接分析方法 |
| CN100376895C (zh) * | 2004-11-03 | 2008-03-26 | 中国科学院计算技术研究所 | 一种使用串联质谱数据鉴定肽的方法 |
| CN100483394C (zh) * | 2006-04-14 | 2009-04-29 | 中国科学院计算技术研究所 | 一种质谱数据处理中噪音基线识别方法 |
| US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
| EP3511973B1 (en) * | 2010-12-28 | 2021-08-04 | Quest Diagnostics Investments LLC | Quantitation of insulin by mass spectrometry |
| GB201110272D0 (en) | 2011-06-17 | 2011-08-03 | Isis Innovation | Metod of detection by mass spectrometry |
| CN203367223U (zh) * | 2012-05-21 | 2013-12-25 | 核工业北京地质研究院 | 热电离飞行时间质谱仪 |
| US10049868B2 (en) * | 2016-12-06 | 2018-08-14 | Rapiscan Systems, Inc. | Apparatus for detecting constituents in a sample and method of using the same |
| CN114383984B (zh) * | 2021-12-06 | 2022-09-23 | 浙江大学 | 一种捕获颗粒物并测量其相态、形貌和化学组分的系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288644A (en) * | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5202563A (en) * | 1991-05-16 | 1993-04-13 | The Johns Hopkins University | Tandem time-of-flight mass spectrometer |
| US5144127A (en) * | 1991-08-02 | 1992-09-01 | Williams Evan R | Surface induced dissociation with reflectron time-of-flight mass spectrometry |
| US5382793A (en) * | 1992-03-06 | 1995-01-17 | Hewlett-Packard Company | Laser desorption ionization mass monitor (LDIM) |
| ATE242485T1 (de) * | 1993-05-28 | 2003-06-15 | Baylor College Medicine | Verfahren und massenspektrometer zur desorption und ionisierung von analyten |
| US6020208A (en) * | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
| US6017693A (en) * | 1994-03-14 | 2000-01-25 | University Of Washington | Identification of nucleotides, amino acids, or carbohydrates by mass spectrometry |
| US5498545A (en) * | 1994-07-21 | 1996-03-12 | Vestal; Marvin L. | Mass spectrometer system and method for matrix-assisted laser desorption measurements |
| US5777324A (en) * | 1996-09-19 | 1998-07-07 | Sequenom, Inc. | Method and apparatus for maldi analysis |
| NZ516848A (en) * | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
| GB9717926D0 (en) * | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
| US6348688B1 (en) * | 1998-02-06 | 2002-02-19 | Perseptive Biosystems | Tandem time-of-flight mass spectrometer with delayed extraction and method for use |
| US6428956B1 (en) * | 1998-03-02 | 2002-08-06 | Isis Pharmaceuticals, Inc. | Mass spectrometric methods for biomolecular screening |
| US6723564B2 (en) * | 1998-05-07 | 2004-04-20 | Sequenom, Inc. | IR MALDI mass spectrometry of nucleic acids using liquid matrices |
-
2000
- 2000-10-11 CA CA002425434A patent/CA2425434A1/en not_active Abandoned
- 2000-10-11 EP EP00973492A patent/EP1327151A2/en not_active Withdrawn
- 2000-10-11 WO PCT/US2000/028261 patent/WO2002031484A2/en not_active Ceased
- 2000-10-12 AU AU1199501A patent/AU1199501A/xx active Pending
- 2000-10-12 CN CNA008199639A patent/CN1474944A/zh active Pending
- 2000-10-12 JP JP2002534819A patent/JP2004511773A/ja active Pending
-
2003
- 2003-04-01 US US10/406,023 patent/US20030219731A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106415260A (zh) * | 2014-06-13 | 2017-02-15 | Dh科技发展私人贸易有限公司 | 使用质谱分析法分析脂质的方法 |
| CN106415260B (zh) * | 2014-06-13 | 2021-04-06 | Dh科技发展私人贸易有限公司 | 使用质谱分析法分析脂质的方法 |
| JP2017534052A (ja) * | 2014-10-30 | 2017-11-16 | ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド | イオン断片化のためのイオンを選択するための方法およびシステム |
Also Published As
| Publication number | Publication date |
|---|---|
| US20030219731A1 (en) | 2003-11-27 |
| WO2002031484A2 (en) | 2002-04-18 |
| AU1199501A (en) | 2002-04-22 |
| WO2002031484A8 (en) | 2003-09-04 |
| WO2002031484A3 (en) | 2002-07-25 |
| EP1327151A2 (en) | 2003-07-16 |
| CA2425434A1 (en) | 2002-04-18 |
| CN1474944A (zh) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020182649A1 (en) | Methods for protein identification, characterization and sequencing by tandem mass spectrometry | |
| US20020195555A1 (en) | Apparatus and methods for affinity capture tandem mass spectrometry | |
| US8525104B2 (en) | Methods for direct biomolecule identification by matrix-assisted laser desorption ionization (MALDI) mass spectrometry | |
| US20100227352A1 (en) | Expression Quantification Using Mass Spectrometry | |
| US10670606B2 (en) | Mass spectrometry analysis of mutant polypeptides in biological samples | |
| JP2004511773A (ja) | アフィニティ捕捉タンデム質量分析を用いた分子相互作用の特性を決定する方法 | |
| CN118393051A (zh) | 通过质谱法定量甲状腺球蛋白 | |
| JP2004524511A (ja) | アフィニティ捕捉タンデム質量分析のための装置および方法 | |
| Mo et al. | Analytical aspects of mass spectrometry and proteomics | |
| JP2007538262A (ja) | 質量分析を使用する発現の定量化 | |
| Matthiesen et al. | Introduction to mass spectrometry-based proteomics | |
| Zhang | Method development of characterization of N-linked glycoproteins in mass spectrometry | |
| DeSouza | Cancer Biomarker Discovery Using Mass Spectrometry | |
| Slade | Application of label-free mass spectrometry-based proteomics to biomarker discovery | |
| Allingham | Development of proteomic techniques for biomarker discovery | |
| Arnott | Basics of TSQ/IT Mass Spectrometry: precursor, product, and neutral loss scanning. ESI and nanospray ionisation |